Stroke/Vascular Neurology News

In this week’s edition, women are less likely than men to return to work after large vessel occlusion stroke; cognitive impairment, headaches and CVD are more common in former college football players; veterans, providers support the addition of integrative medicine for chronic headaches; and more.

Angiotensin receptor blockers may reduce progression from mild cognitive impairment to dementia in patients undergoing antihypertensive treatment, researchers wrote in Hypertension.

Endovascular therapy is now a standard treatment for select patients with severe ischemic stroke to improve the likelihood of functional recovery; yet there remains a paucity of research on outcomes by sex and gender.

Antibodies produced in response to COVID-19 may mistakenly target cells essential to the blood-brain barrier, which can cause bleeds and clots in patients and increase the risk for stroke, researchers reported in Brain.

Treatment with tenecteplase in an Australian mobile stroke unit was safe and resulted in improved outcomes compared with alteplase, according to a study published in The Lancet Neurology.

A sensor-equipped computer program was nearly 80% effective in identifying and counting arm movements in patients undergoing stroke rehabilitation, researchers from NYU Grossman School of Medicine announced.

DENVER – Individuals who had migraine with aura were more likely to have atrial fibrillation compared with those who had a migraine without aura, a presenter said at the American Headache Society annual meeting.

An analysis of data registries from three countries showed the AstraZeneca vaccine was associated with small but increased rates of hospital contacts for thromboembolic coagulation disorders, especially for thrombocytopenia.

Patients treated for stroke at non-urban hospitals in New Zealand experience poorer outcomes and face reduced access to crucial stroke interventions across the entire care spectrum, according to a study published in Neurology.

Inclisiran effectively and safely lowered LDL in patients with hyperlipidemia and prior cerebrovascular disease, according to a pooled analysis of the three ORION trials presented at the National Lipid Association Scientific Sessions.